OSLI Retina

August 2020

Issue link: http://osliretina.healio.com/i/1279094

Contents of this Issue


Page 8 of 59

Practical Retina August 2020 · Vol. 51, No. 8 427 6. Patel SN, Groth S, Sternberg P Jr. The emergence of private equity in ophthalmology. JAMA Ophthalmol. 2019;137(6):601-602. https://doi. org/10.1001/jamaophthalmol.2019.0964 PMID:31046063 7. United States Files False Claims Act Complaint Against Compounding Pharmacy, Private Equity Firm, and Two Pharmacy Executives Alleging Payment of Kickbacks. United States Department of Justice. The Unit- ed States Attorney's Office, Southern District of Florida. https://www. justice.gov/usao-sdfl/pr/united-states-files-false-claims-act-complaint- against-compounding-pharmacy-private. Published February 23, 2018. Accessed November 24, 2019. 8. Family Dermatology PcC Agrees to Pay United States More Than $3.2 Million to Settle Alleged False Claims Act Violations. The United States Department of Justice, Office of Public Affairs. https://www.justice.gov/ opa/pr/family-dermatology-pcc-agrees-pay-united-states-more-32-mil- lion-settle-alleged-false-claims. Published April 21, 2015. Accessed No- vember 24, 2019. 9. Hafner K, Palmer G. Skin Cancers Rise, Along With Questionable Treat- ments. https://www.nytimes.com/2017/11/20/health/dermatology-skin- cancer.html. Published November 20, 2017. Accessed November 24, 2019. 10. Court E. American Medical Association to investigate whether private- equity-owned practices put profits over patients. MarketWatch. https:// www.marketwatch.com/story/responding-to-doctors-concerns-ameri- can-medical-association-will-investigate-role-of-private-equity-and-oth- er-companies-2018-06-18. Published June 18, 2018. Accessed Novem- ber 24, 2019. 11. Private Equity Spotlight – May 2016. Preqin. https://www.preqin.com/ insights/spotlight-newsletters/private-equity-spotlight-may-2016/14428. Published May 13, 2016. Accessed November 24, 2019. 12. Baker-Schena L. Private Equity and Ophthalmology. Eyenet Magazine. 2019;(Nov):39-44. 13. Sharfstein JM, Slocum J. Private Equity and Dermatology – First, Do No Harm. JAMA Dermatol. 2019 July 24. doi: 10.1001/jamaderma- tol.2019.1322. Online ahead of print. https://doi.org/10.1001/jamader- matol.2019.1322 PMID:31339511 Veeral Sheth, MD, MBA, can be reached at 15947 W 127th St., Suite E, Lem- ont, IL 60439; email: vsheth@gmail.com. Seenu M. Hariprasad, MD, can be reached at University of Chicago, Department of Ophthalmology and Visual Science, 5841 S. Maryland Ave., Room S-439, Chicago, IL 60637; email: retina@uchicago.edu. Dilsher S. Dhoot, MD, can be reached at California Retina Consultants, 525 E. Micheltorena Street, Suite A, Santa Barbara, CA 93103; email: ddhoot@ yahoo.com. Disclosures: Drs. Sheth and Dhoot report no relevant financial disclosures. Dr. Hariprasad is a consultant or on the speakers bureau for Allergan, Novartis, Biogen, Graybug, EyePoint, Alimera Sciences, Spark, and Regeneron.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - August 2020